O’Regan on Protocols, Best Practices, and Virtual Etiquette for Cancer Care in Light of COVID-19
October 5th 2020In our exclusive interview, O’Regan discusses the protocols the University of Wisconsin Carbone Cancer Center has put into place in light of COVID-19, the rise of telemedicine, best practices for in-person visits in the clinic, and the importance of maintaining well visits throughout the pandemic.
The Prostate Cancer Paradox Revisited
September 25th 2019Conflicting guidelines on prostate-specific antigen testing have affected trends on disease presentation and, potentially, the treatment outcomes for many men with this disease. New agents and powerful new imaging tools have added yet more complexity to the decision process. Therefore, more investigation and cooperation on multiple levels is needed to define appropriate standards of care.
Dr. O'Regan on Future of Chemotherapy in Breast Cancer
December 11th 2018Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the role of chemotherapy as treatment continues to advance in breast cancer.
Dr. O'Regan Discusses the Future of Treatment in HER2+ Breast Cancer
May 16th 2017Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.
Patient-Derived Cancer Stem Cells Offer Diagnostic and Therapeutic Potential in Brain Cancer
March 1st 2017A brain tumor research group at the UW Carbone Cancer Center focuses on biological studies of patient-derived glioblastoma multiforme (GBM) cancer stem cells, combined with analysis of patient-matched serum-cultured GBM and an annotated GBM tissue microarray, to identify clinically relevant biomarkers.